

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
October 10, 2018

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh, PharmD, BCPS

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Massimo Cristofanilli, MD, FACP

Associate Director of Translational Research and
Precision Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Christian S. Hinrichs, MD

Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology
Branch
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Bethesda, Maryland

Heidi D. Klepin, MD, MS

Associate Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Grzegorz S. Nowakowski, MD

Associate Professor of Medicine and Oncology
Mayo Clinic Rochester
Rochester, Minnesota

Brian I. Rini, MD, FACP

(Chairperson)
Professor of Medicine, Lerner College of Medicine
Leader, GU Program
Department of Hematology and Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Thomas S. Uldrick, MD, MS

Deputy Head, Global Oncology
Associate Member, Vaccine and Infectious Disease
Division
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 10, 2018

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Phuong Khanh (P.K.) Morrow, MD, FACP

(Industry Representative)

Executive Medical Director, Amgen Oncology
Therapeutic Area Head, US Medical Organization
Thousand Oaks, California

TEMPORARY MEMBERS (Voting)

Andy Chen, MD, PhD

Associate Professor of Medicine
Division of Hematology and Medical Oncology
Oregon Health and Science University
Portland, Oregon

Jerry M. Collins, PhD

Associate Director for Developmental Therapeutics
Division of Cancer Treatment and Diagnosis
NCI, NIH
Bethesda, Maryland

William S. Hancock, PhD

Bradstreet Chair in Bioanalytical Chemistry,
Barnett Institute and Department of Chemistry and
Chemical Biology
Northeastern University
Boston, Massachusetts

Randy Hawkins, MD

(Acting Consumer Representative)
Private Practice
Inglewood, California

Adel H. Karara, PhD, FCP

Professor of Pharmaceutical Sciences
University of Maryland Eastern Shore
Princess Anne, Maryland

Eric O. Long, PhD

Head, Molecular and Cellular Immunology
Laboratory of Immunogenetics
National Institute of Allergy and Infectious
Diseases, NIH
Rockville, Maryland

Tracy G. Matson

(Patient Representative)
Little Rock, Arkansas

Paul J. Smith, PhD

Associate Professor of Statistics
Director, Mathematical Statistics Program
University of Maryland
College Park, Maryland

Scott A. Waldman, MD, PhD

Chair, Department of Pharmacology and
Experimental Therapeutics
Samuel MV Hamilton Professor
Thomas Jefferson University
Director, GI Malignancies Program
Kimmel Cancer Center
Philadelphia, Pennsylvania

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
October 10, 2018

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Ann Farrell, MD

Director
Division of Hematology Products (DHP)
Office of Hematology and Oncology Products
(OHOP)
Office of New Drugs (OND), CDER, FDA

Nicole Gormley, MD

Deputy Director (Acting)
DHP, OHOP, OND, CDER, FDA

Vishal Bhatnagar, MD

Medical Officer Team Leader (Acting)
DHP, OHOP, OND, CDER, FDA

Sue Lim, MD

Director of the Scientific Review Staff
Therapeutic Biologics and Biosimilars Staff (TBBS)
OND, CDER, FDA

Steven Kozlowski, MD

Director
Office of Biotechnology Products (OBP)
Office of Pharmaceutical Quality (OPQ)
CDER, FDA

Christopher Downey, PhD

Review Chief
Division of Biotechnology Review and Research IV
OBP, OPQ, CDER, FDA